Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

AFTR: a fifth human B-cell-specific surface antigen.

J M Pesando1, M A Stucki

  • 1Division of Clinical Immunology, Biomembrane Institute, Seattle, Washington.

Human Immunology
|March 1, 1990
PubMed
Summary

Researchers identified a new B-cell surface antigen, AFTR, present on most B-cell cancers and normal B cells. This discovery offers a potential new target for B-cell malignancies and diagnostics.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

CD6 dependent interactions of T cells and keratinocytes: functional evidence for a second CD6 ligand on gamma-interferon activated keratinocytes.

Immunology letters·1997
Same author

Diversity of sites for measles virus binding and for inactivation of complement C3b and C4b on membrane cofactor protein CD46.

The Journal of biological chemistry·1995
Same author

Cloning, mapping, and characterization of activated leukocyte-cell adhesion molecule (ALCAM), a CD6 ligand.

The Journal of experimental medicine·1995
Same author

Identification and characterization of a 100-kD ligand for CD6 on human thymic epithelial cells.

The Journal of experimental medicine·1995
Same author

Effect of liposomes containing sodium butyrate conjugated with anti-CD19 monoclonal antibody on in vitro and in vivo growth of malignant lymphoma.

Cancer research·1990
Same author

CD19 is functionally and physically associated with surface immunoglobulin.

The Journal of experimental medicine·1989

Area of Science:

  • Immunology
  • Oncology
  • Biochemistry

Background:

  • B-cell specific surface antigens are crucial for understanding B-cell development and malignancy.
  • Existing markers like CD19 and CD20 are vital for B-cell research and therapy.
  • The identification of novel B-cell antigens can lead to improved diagnostic and therapeutic strategies.

Purpose of the Study:

  • To identify and characterize a novel fifth B-cell-specific surface antigen.
  • To determine the expression pattern of this antigen on various B-cell populations and malignancies.
  • To compare the characteristics of this new antigen with known B-cell surface markers.

Main Methods:

  • Utilized murine monoclonal antibodies to detect and isolate the antigen.
  • Employed immune precipitation and SDS-PAGE for molecular characterization.
  • Analyzed antigen expression on malignant and normal B-cell lines and primary cells.
  • Investigated antigen modulation upon antibody incubation at 37°C.

Main Results:

  • Identified a novel B-cell antigen, AFTR, detected by three monoclonal antibodies.
  • AFTR is expressed on malignant B-cell lines (except plasma cells) and malignant B cells from all patients tested, including pre-B-cell acute lymphoblastic leukemia.
  • AFTR is present on normal B cells from bone marrow, blood, and tonsil but weakly on EBV-transformed B cells.
  • Molecular weights of 38 and 42 kd were observed, with distinct expression patterns and modulation behavior compared to CD20, CD19, and surface immunoglobulin.

Conclusions:

  • AFTR represents a distinct B-cell-specific surface antigen.
  • Its presence on malignant B cells and normal B cells makes it a potential target for B-cell-related diagnostics and therapeutics.
  • AFTR's unique characteristics differentiate it from previously identified B-cell antigens, including CD72.

Related Experiment Videos